Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969900 | 1.00 | MAPT (0.51) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL356454 | 1.00 | MAPT (0.51) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL31147657 | 1.00 | MAPT (0.51) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL31167959 | 1.00 | MAPT (0.51) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL2688152 | 0.90 | MAPT (0.57) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL2688150 | 0.90 | MAPT (0.57) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL2688155 | 0.90 | MAPT (0.57) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL7272150 | 0.87 | MAOB (0.52) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL7272155 | 0.87 | MAOB (0.52) | MAPTALDH1A1MEN1APPSNCA | |
| SCHEMBL16082212 | 0.86 | HTT (0.57) | MAPTALDH1A1MEN1APPSNCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B9 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3339303-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | PFIZER INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-3339303-A1 | ARYL AND HETEROARYL FUSED LACTAMS | Pfizer Inc (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2935238-B1 | ARYL AND HETEROARYL FUSED LACTAMS | PFIZER (US) | 2017-12-27 | — | — | EP | disclosed |
| US-20070191640-A1 | Process for the synthesis of substituted alpha-aminoindan derivatives | PPG-SIPSY (FR) | 2007-08-16 | — | — | US | disclosed |
| EP-1797030-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF INDANYLAMINE OR AMINOTETRALIN DERIVATIVES AND NOVEL INTERMEDIATES | Teva Pharmaceuticals USA, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | PPG-SIPSY (FR) | 2007-06-07 | — | — | US | disclosed |
| EP-1716097-A2 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | PPG-Sipsy S.C.A. (FR) | 2006-11-02 | — | — | EP | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| US-20060199974-A1 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-09-07 | — | — | US | disclosed |
| WO-2006029135-A1 | IMPROVED PROCESS FOR THE SYNTHESIS OF INDANYLAMINE OR AMINOTETRALIN DERIVATIVES AND NOVEL INTERMEDIATES | TEVA PHARMACEUTICAL USA, INC (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052639-A1 | Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates | TEVA PHARMACEUTICALS USA, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1574498-A1 | Process for the synthesis of substituted alpha-aminoindan derivatives | PPG-Sipsy (FR) | 2005-09-14 | — | — | EP | disclosed |
| WO-2005063687-A2 | NEW PROCESS FOR THE SYNTHESIS OF ENEAMIDE DERIVATIVES | PPG-SIPSY (FR) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | MAPT 12/4885ALDH1A1 2230/4885MEN1 2282/4885 |
| US-20060199974-A1 | propynylaminoindans including alkoxy or alkylcarbamates derivatives, prepared by reduction of indanones in the presence of hydrogenation catalysts to form indanols and reacting the indanols with propargylamine under nucleophilic substitution to form drugs for the treatment of nervous system disorders | ICMT, INMT, PNMT | MAPT 660/4885ALDH1A1 159/4885MEN1 2307/4885 |
| US-20070191640-A1 | Process for the synthesis of substituted alpha-aminoindan derivatives | ALDH7A1, ALAD, ASPH | MAPT 4049/4885ALDH1A1 199/4885MEN1 2107/4885 |
| US-20070129573-A1 | Process for the synthesis of eneamide derivatives | CBR3, CBR1, CYB5R3 | MAPT 4617/4885ALDH1A1 3804/4885MEN1 2613/4885 |
| US-10246433-B2 | Aryl and heteroaryl fused lactams | CCNY, MLX, NFXL1 | MAPT 4186/4885ALDH1A1 2245/4885MEN1 155/4885 |
| US-20060052639-A1 | Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates | IDO1, INMT, TDO2 | MAPT 1649/4885ALDH1A1 666/4885MEN1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.